For Patients and Visitors
Vanderbilt University Medical Center: For Employees, Researchers, and Students

Vanderbilt study finds no heart risk in ADHD medications

November 1, 2011

William Cooper, M.D., MPH, professor of Pediatrics and Preventive Medicine

William Cooper, M.D., MPH, professor of Pediatrics and Preventive Medicine

Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.

The study, published online today by the New England Journal of Medicine (NEJM) and authored by William Cooper, M.D., MPH, a Vanderbilt Professor of Pediatrics and Preventive Medicine, is the largest ever to examine potential risks posed by drugs to treat ADHD.

“It should be reassuring that we found no evidence that these drugs increase the risk of serious cardiovascular events on a population basis,” Cooper said.

“However, each child is unique, so families and providers need to work together to make informed decisions about the best options for their children. This is especially true for children who have any chronic health conditions or special health needs.”

ADHD, the most common neurobehavioral disorder in childhood, is characterized by inattention, overactivity and impulsivity.

Cooper and colleagues reviewed medical records from four health plans for more than 1.2 million children and young adults ages 2-24. Data collected from 1998-2005 were examined for serious cardiovascular events including sudden cardiac death, heart attack and stroke.

Current users of ADHD medications and their health records were compared with individuals who were not using ADHD medications.

Over the seven-year period, 81 cases of serious heart problems, or about three cases per 100,000, were documented. There was no significant increase in risk of these events for patients who used ADHD medications compared with those who did not, Cooper said.

The Food and Drug Administration issued a black-box advisory in 2006, linking ADHD medications and potential heart risk. Then, in 2008, the American Heart Association (AHA) reviewed existing research and concluded it was reasonable for physicians to obtain an electrocardiogram (EKG) before prescribing ADHD medications.

“We hope that the study will provide evidence to guide future recommendations for whether children without a history of heart problems should be tested before starting ADHD medications,” Cooper said.

The study was supported by the Agency for Healthcare Research and Quality’s (AHRQ) Effective Health Care program and the FDA.

Attached images:
Cooper01- Portrait of William Cooper, M.D., MPH, Vanderbilt Professor of Pediatrics and Preventive Medicine, photo by Neil Brake
Cooper02- William Cooper, M.D., MPH, Vanderbilt Professor of Pediatrics and Preventive Medicine, looks at medications commonly prescribed to treat ADHD, photo by Neil Brake


Media Inquiries:
Craig Boerner
Senior Information Officer / National News Director
News & Communications
Phone: 615-322-4747

Copyright © 2021 by Vanderbilt University Medical Center    |    1211 Medical Center Drive    |    Nashville, TN 37232    |    (615) 322-5000
Vanderbilt University is committed to principles of equal opportunity and affirmative action.